Centrexion Therapeutics CNTX 深 沪
等待开盘 10-03 09:30:00 美东时间
1.005
+0.035
+3.62%
华盛通- 最 高1.02
- 今 开0.9899
- 成交量 28.12万股
- 最 低 0.9899
- 昨 收 0.9699
- 总市值 9015.27万
- 52周最高 2.5899
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 0.49
- 委 比 -13.28%
- 总股本 8970.42万
- 历史最高 10.87
- 量 比 2.18
- 振 幅 3.10%
- 历史最低 0.47
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Initiates Coverage On Context Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.
10-02 20:40
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Guggenheim Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $5
Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $5.
09-18 21:02
Context Therapeutics Granted Nasdaq Extension for Compliance
Context Therapeutics ( ($CNTX) ) has shared an update. On August 28, 2025, Cont...
09-02 19:59
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. (Nasdaq: CNTX) announced its participation in two investor conferences: the Cantor Global Healthcare Conference 2025 on September 3 and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, both in New York. The company is advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio including CTIM-76, CT-95, and CT-202. Further details or meeting requests can be obtained via I...
08-27 11:30
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
08-22 12:00
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will release its Q2 2025 financial results and host a webcast/conference call on Monday, August 11, 2025, at 8:00 AM ET. The event will provide updates on the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. The call can be accessed via dial-in numbers 1-877-407-9716 (US) or 1-201-493-6779 (Intl.), using conference ID 13754...
08-08 20:01
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $5 to $4.
08-07 18:57
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
Context Therapeutics reported Q2 2025 financial results with $83.5 million in cash and expects to fund operations into 2027. The company is advancing its T cell engaging bispecific antibody pipeline, including CTIM-76 and CT-95, with initial data expected in 2026. Notable updates include CT-95's first patient dosing and presentations at major oncology conferences. R&D expenses rose to $7.8 million due to pipeline expansion and higher personnel co...
08-06 20:11
Concentrix Releases New iX Hero™ Agentic AI Features
<p>Concentrix Corporation has launched the latest version of iX Hero, part of its Intelligent Experience product suite, featuring new capabilities Harmony and Clarity. These enhancements利用先进的AI技术提升客户互动的清晰度和背景噪音抑制，显著提升了客户沟通分数和净推荐分数。客户PODS表示，使用iX Hero后销售转化率大幅提升。Concentrix高管强调，这些功能助力客户进入新市场并优化全球团队。产品现全球可用，并针对菲律宾、印度和拉美团队进行了优化。</p>
07-30 20:05
